Background
An abnormally elevated level of amyloid-β peptide (Aβ) in the brain is one of the prominent features of Alzheimer's disease (AD) [1] . Aβ is normally produced by neurons and cleared through degradation by proteinases within the brain [2] [3] [4] , as well as through elimination from the brain to the circulating blood via an efflux transport system at the blood-brain barrier (BBB) [5, 6] . It has been proposed that impairment of cerebral Aβ clearance leads to abnormally elevated brain Aβ levels in late-onset AD which accounts for more than 90% of all cases of AD. On the other hand, somatostatin was reported to promote the degradation of Aβ in the brain [7] . Anti-Aβ antibodies such as m266 in circulating blood were also proposed to enhance Aβ efflux transport from brain to blood [8] , though we subsequently found that anti-Aβ antibodies did not promote Aβ elimination from brain to the blood across the BBB [9] . Identification of factors that promote cerebral Aβ clearance would be helpful in developing new therapeutic approaches and agents for treatment and prevention of AD.
Epidemiological studies have suggested that a low level of serum 25-hydroxyvitamin D 3 (25(OH)D3), the major circulating form of vitamin D, is associated with cognitive impairment in elderly persons [10] [11] [12] and is a risk factor for AD [13, 14] . Furthermore, it was reported that single nucleotide polymorphisms in the vitamin D receptor (VDR) gene increase the risk of impairment of cognitive function and developing AD [15, 16] , suggesting a relation between serum vitamin D levels and risk of AD. It was also reported that low levels of serum 25 (OH)D3 are associated with increased risk for cardiovascular diseases, hypertension and diabetes mellitus [17] [18] [19] [20] , which are associated with vascular dysfunction. Since clinical studies have provided evidence that vascular dysfunction plays an important role in early progression of AD [21] [22] [23] , we hypothesized that serum vitamin D affects the function of brain capillaries, including the brain-to-blood efflux transport of Aβ.
The purpose of the present study was to investigate the effect of 1α,25-dihydroxyvitamin D 3 (1,25(OH) 2 D3), the physiologically active form of vitamin D, on the elimination of human Aβ(1-40) (hAβ ) from mouse brain across the BBB using the Brain Efflux Index (BEI) method. We also examined the internalization of [
125 I] hAβ in conditionally immortalized mouse brain capillary endothelial cells (TM-BBB4), as an in vitro BBB model [24] .
Methods

Animals
Male C57BL/6 mice (8-10 weeks old) were purchased from Japan SLC (Hamamatsu, Japan). All experiments were approved by the Animal Care Committee of the Graduate School of Pharmaceutical Sciences, Tohoku University. (24, 48 , or 72 h), the in vivo brain elimination experiments were performed using the intracerebral microinjection technique [25] . Briefly, mice were anesthetized with an intramuscular injection of xylazine (1.22 mg/kg) and ketamine (125 mg/kg), and placed in a stereotaxic frame (SRS-6; Narishige, Tokyo, Japan) that determines the coordinates of the mouse brain coinciding with the secondary somatosensory cortex 2 (S2) region. A small hole was made 3.8 mm lateral to the bregma, and a fine injection needle fitted to a 5.0 μl microsyringe (Hamilton, Reno, NE, USA) was advanced to a depth of 2.5 mm. and [ 3 H]dextran in an ECF buffer was administered into the S2 region over a period of 30 sec. After microinjection, the microsyringe was left in place for 4 min to minimize any backflow. At 5, 30 or 60 min after microinjection, ipsilateral (left) and contralateral (right) cerebrum and cerebellum were excised and dissolved in 2.0 ml 2 M NaOH at 60°C for 1 h. The 125 I and 3 H radioactivities of the samples were measured in a γ-counter (ART300, Aloka, Tokyo, Japan) for 3 min and a liquid scintillation counter (TRI-CARB2050CA, Packard Instruments, Meriden, CT, USA) for 5 min, respectively. The BEI was defined by Equation (1) , and the percentage of substrate remaining in the ipsilateral cerebrum (100-BEI) was determined using Equation (2) The apparent elimination rate constant (k el ) was determined from the slope given by fitting a semilogarithmic plot of (100-BEI) versus time, using the nonlinear least-squares regression analysis program MULTI [27] .
Reagents
Quantification of endogenous soluble mouse Ab by ELISA Endogenous soluble Aβ in mouse brain extracts was quantified according to the previously-reported method [28] . Twenty-four h after 1,25(OH) 2 D3 (1 μg/ mouse) or vehicle injection i.p., mice were sacrificed and the brains were rapidly isolated. The cerebellum and olfactory bulbs were discarded, and the remaining brains were snap-frozen in liquid nitrogen. To extract soluble endogenous full-length mouse Aβ , the frozen brains were homogenized in 10 volumes of ice-cold Tris buffer (50 mM Tris-HCl, 250 mM sucrose and protease inhibitor cocktail (Sigma, St. Louis, MO, USA)). Samples were mixed in diethylamine (DEA) to yield 0.4% concentration and centrifuged at 100,000 × g for 45 min at 4°C. The resultant supernatant was neutralized in 1/10 volume of 0.5 M Tris-HCl (pH 6.8) and used for analysis. Endogenous full-length mouse Aβ(1-40) levels were determined using an ELISA (IBL, Gunma, Japan) according to the manufacturer's protocol.
TM-BBB4 cell culture
The TM-BBB4 cell line, established from transgenic mice harboring the temperature-sensitive SV40 large Tantigen gene [24] , was used in this study. TM-BBB4 cells were cultured at 33°C in Dulbecco's modified Eagle's medium (DMEM; Nissui Pharmaceutical Co., Tokyo, Japan), supplemented with 20 mM NaHCO 3 , 2 mM L-glutamine, 15 ng/ml endothelial cell growth factor, 100 U/ml benzyl penicillin, 100 mg/ml streptomycin sulfate, and 10% fetal bovine serum (Moregate, Bulimba, Australia) in an atmosphere of 95% air and 5% CO 2 .
RT-PCR analysis
Isolated mouse brain capillaries were prepared as described previously [29] . Total RNA was prepared from isolated mouse brain capillaries, TM-BBB4 cells and mouse brain using TRIzol reagent (Life Technologies, Grand Island, NY, USA) and RNeasy plus kit (Qiagen, Tokyo, Japan) according to the manufacturer's protocols. Single-stranded cDNA was prepared from 1 μg of total RNA by means of reverse transcription (DNA Ligation Kit, Takara, Osaka, Japan) using oligo dT primer. The PCR was performed with GeneAmp (PCR system 9700, Perkin-Elmer, Norwalk, CT, USA) using specific primers through 1 cycle of 94°C for 2 min, and 35 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 1 min and finally 72°C for a further 5 min. The sequences of the primers were as follows: sense primer 5'-CGA TGC CCA CCA CAA GAC CTAC-3' and antisense primer 5'-CAG CAT GGA GAG CGG AGA CAG-3' for vitamin D receptor (GenBank Accession Number, NM_009504), sense primer 5'-TTT GAG ACC TTC AAC ACCC C-3' and antisense primer 5'-ATA GCT CTT CTC CAG GGA GG-3' for β-actin (GenBank Accession Number, NM_031144). The RT-PCR of each sample RNA in the absence of reverse transcriptase was used as a negative control. The RT-PCR products were separated by electrophoresis on an agarose gel in the presence of ethidium bromide (0.6 μg/mL) and visualized using an imager (EPIPRO 7000; Aisin, Aichi, Japan). The 125 I radioactivity was measured using a γ-counter (ART310, Aloka, Tokyo, Japan). The protein content of the cultured cells was measured using a DC protein assay kit (Bio-Rad, Hercules, CA, USA) with bovine serum albumin as a standard.
In vitro internalization study in TM-
Data analysis
Unless otherwise indicated, all data represent the mean ± SEM. Unpaired two-tailed Student's t-tests were used to determine the significance of differences between the means of two groups. One-way analysis of variance followed by Dunnett's test was used to assess the statistical significance of differences among the means of more than two groups. (Figure 2A) .
Results
Effect
The effect of time after 1,25(OH) 2 D3 administration was examined at the amount of 1 μg/mouse, which exhibited the greatest effect in Figure 2A . As shown in Figure 2B , RT-PCR analysis was performed to determine VDR expression in mouse brain, mouse isolated brain capillaries and TM-BBB4 cells [24] . A band of the size predicted for VDR was obtained in each case (Figure 4) , suggesting that VDR is expressed in mouse brain capillary endothelial cells.
Effect of forskolin on [
125 I]hAb(1-40) elimination from mouse brain 1,25(OH) 2 D3 also exerts non-genomic biological effects via a complex signaling process, which has been reported to involve increased levels of cyclic AMP (cAMP) [30] and activation of the mitogen-activated protein kinase kinase (MEK) pathway [31, 32] . Since forskolin increases the level of cAMP following activation of adenylyl cyclase in vitro, the effect of forskolin on the remaining percentage of [ 125 I]hAβ in the ipsilateral cerebrum was examined ( Figure 5 ). Twenty-four h after i.p. administration of single-dose forskolin ( 
Discussion
Our results indicate that 1,25(OH) 2 D3 enhances cerebral clearance of Aβ(1-40) from mouse brain across the BBB. Specifically, we have obtained in vivo evidence that 1,25 (OH) 2 D3 treatment significantly increased [
125 I]hAβ(1-40) elimination from mouse brain across the BBB (Figurs 1, 2) , and resulted in a significant reduction in the level of endogenous soluble Aβ in the brain. It was reported that rat brain capillary endothelial cells possess iodide efflux activity and that the activity was affected by intracellular ATP level [34] . Therefore, we cannot rule out the possibility that the enhancement effect of 1,25(OH) 2 D3 shown in Figure 1 is partially due to facilitation of free [
125 I] elimination from the brain. Nevertheless, the reduction of endogenous Aβ(1-40) level in the brain by 1,25(OH) 2 D3 treatment, as shown in Figure 3, suggests that, at least, hAβ(1-40) elimination from the brain was enhanced by the treatment.
The biological effects of 1,25(OH) 2 D3 are mediated by a mixture of genomic and non-genomic actions. The genomic action of 1,25(OH) 2 D3 is mediated by binding of VDR-retinoid × receptor (RXR) complex at the vitamin D response elements on target genes. RT-PCR analysis confirmed the expression of VDR mRNA in mouse brain capillaries (Figure 4) . We previously demonstrated the expression of RXRs in rat brain capillaries [35] . These results indicate that brain capillary endothelial cells possess VDR-mediated genomic pathway(s), which may be involved in the enhancement of Aβ efflux transport activity.
As regards non-genomic actions, 1,25(OH) 2 D3 has been proposed to play roles in the generation of intracellular second messengers and various signal-transduction cascades [36, 37] . 1,25(OH) 2 D3 increased the intracellular level of cAMP in several cell lines as efficiently as did forskolin [30, 38] , and the MEK-mitogenactivated protein kinase (MAPK)-extracellular signalregulated kinase (ERK) signaling pathway is known to be activated through elevation of intracellular cAMP. The present BEI study demonstrated that forskolin enhanced [
125 I]hAβ(1-40) elimination from mouse brain (Figure 4 ) and the in vitro uptake study showed that forskolin increased [
125 I]hAβ(1-40) internalization into TM-BBB4 cells, and this action was inhibited by MEK inhibitor ( Figure 6B ). These results suggest that the MEK-MAPK-ERK signaling pathway is involved in enhancing the brain-to-blood efflux transport of hAβ at the BBB. Therefore, 1,25(OH) 2 D3-mediated enhancement of brain-to-blood hAβ(1-40) efflux transport is likely to involve both genomic and nongenomic actions of 1,25(OH) 2 D3. The enhancing effect of forskolin on [
125 I]hAβ(1-40) elimination (16.4%, Figure 5 ) is smaller than that of 1,25(OH) 2 D3 (25.4%, Figure 1A ). This slight difference may be explained by a difference in the activating activity of 1,25(OH) 2 D3 and forskolin at different doses, although it is also possible that forskolin activated only a part of the signaling pathways activated by 1,25(OH) 2 D3.
TM-BBB4 cells retain the expression of various molecules and functions of the in vivo BBB [39] . However, the cells do not have polarity, and internalization into the cells may therefore reflect both uptake from the brain to the brain capillary endothelial cells and from the blood to the brain capillary endothelial cells 125 I]hAβ(1-40) internalization and a P-glycoprotein substrate, verapamil, did not inhibit the uptake [40] .
Soluble Aβ levels correlate with synaptic dysfunction in AD brain [41] [42] [43] , and soluble Aβ dimers and oligomers initially generated from Aβ monomers are involved in the impairment of synaptic plasticity and memory [44, 45] . Our present findings indicate that 1,25(OH) 2 D3 modulates brain-to-blood efflux transport of hAβ at the BBB, and we therefore consider that impairment of 1,25(OH) 2 D3 signaling leads to a decrease in the brain-to-blood efflux transport activity of hAβ at the BBB, which in turn results in an increase of Aβ levels in the brain. Clinical data suggest that low serum 25(OH)D3 is associated with increased risk of cognitive impairment in elderly people [10] [11] [12] , and higher serum 25(OH)D3 levels were found to be associated with better cognitive test performance in AD patients [14] . Epidemiological studies support an association between VDR gene polymorphisms in the ligand-binding site and the development of late-onset AD [15, 16] . These relations between vitamin D status and AD development seem likely to arise, at least partially, from impairment of the brain-to-blood Aβ efflux transport activity at the BBB due to attenuation of basal 1,25(OH) 2 D3-mediated signaling in brain capillary endothelial cells.
Reduction of Aβ in the CNS is considered to be a primary therapeutic target for AD. Based on our findings here, 1,25(OH) 2 D3 appears to be a candidate agent for reduction of Aβ(1-40) level in the brain through enhancement of Aβ elimination across the BBB. The enhancing effect of 1,25(OH) 2 D3 was observed at 24 h after administration, but was not observed at 48 h or 72 h ( Figure 2B ). This is likely to be due to rapid clearance of 1,25(OH) 2 D3 from the circulation, since the plasma concentration of 1,25(OH) 2 D3 reaches a maximum within 2 h and returns to baseline 24 h after i.p. administration [46] . The first experiment shown in Figure 1 was conducted at 24 h after the treatment, to allow sufficient time for functional expression, which involves following gene induction, protein synthesis and translocation. Several in vivo studies have examined the effect of vitamin D3 at 24 h after the last treatment [47] [48] [49] .
To maintain the enhancing effect, repeated administration of 1,25(OH) 2 D3 would be necessary. However, an effective dose of 1,25(OH) 2 D3 might induce adverse effects such as hypercalcemia, because mice receiving over 0.1 μg of 1,25(OH) 2 D3 every other day for 2 weeks had hypercalcemia of over 12 mg/dL [50] . Indeed, mice exhibited reduced body weight and abnormal behavior from day 4 during treatment with 1,25(OH) 2 D3 (1 μg/ day, data not shown).
Several vitamin D analogues appear to induce less hypercalcemia than 1,25(OH) 2 D3, but might retain the Aβ-transport-enhancing activity of 1,25(OH) 2 D3. However, paricalcitol, a vitamin D analogue, did not significantly enhance [
125 I]hAβ(1-40) elimination from mouse brain (data not shown). Therefore, 1,25(OH) 2 D3 and its analogues are unlikely to be candidate disease-modifying agents for AD. Nevertheless, since serum 25(OH)D3 levels tend to decrease with aging [51] , maintaining a normal serum level (32 to 70 ng/mL) could be helpful for prevention of AD. Furthermore, since complex genomic and nongenomic pathways appear to be involved in the action of 1,25(OH) 2 D3, separation of these effects by structural modification might be feasible. The present in vivo and in vitro results suggest that the increase in cAMP levels by forskolin might be a candidate pathway for disease-modification of AD, although the in vivo effects of forskolin are still poorly understood.
Conclusions
Our results indicate that 1,25(OH) 2 D3 plays a role in enhancing the Aβ(1-40) efflux transport process at the BBB. Compounds that activate cAMP signaling may be candidate therapeutic agents for prevention and treatment of AD through functional modulation of Aβ efflux at the BBB. TM-BBB4 cells should be a good model for studying the mechanism of hAβ(1-40) efflux transport at the BBB, and also for screening compounds that enhance the hAβ(1-40) efflux transport activity. 
